CD38 and Miyoshi myopathy: SAR442257 is a trispecific T cell‐engaging antibody that targets CD38 on MM cells, CD3 on T cells, and CD28 on both cell types, offering extensive potential for treating patients resistant to both CD38 monoclonal antibodies and BCMA‐targeted therapy.250